- MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1aC Gasperini
Department of Neuroscience, S Camillo Forlanini Hospital, Rome, Italy
Mult Scler 8:119-23. 2002..The only parameter that predicted brain volume decrease by 2 years of IFNbeta-1a treatment was the mean volume of enhancing lesions over the 6-month pretreatment period...
- New oral drugs for multiple sclerosisClaudio Gasperini
Centro Sclerosi Multipla, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
Neurol Sci 30:S179-83. 2009..Several pivotal reports have provided promising results for new oral therapies evaluating the safety and efficacy of new agents including fingolimod, fumaric acid, cladribine, teriflunomide and laquinimod...
- Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesClaudio Gasperini
Multiple Sclerosis Center, S Camillo Forlanini, Neurosciences, Circonvallazione Gianicolense 87, Rome 00152, Italy
Expert Opin Investig Drugs 22:1243-53. 2013..Despite the standard of care for patients with MS is significantly improved in recent years, there is still room for improvement in terms of effectiveness and also compliance...
- Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approachClaudio Gasperini
Department of Neurosciences, S Camillo Forlanini Hospital, University of Rome Sapienza, Rome, Italy
Drug Des Devel Ther 6:175-86. 2012..We summarily review the oral compounds in study, focusing on the recent development, approval and the clinical experience with FTY720...
- Emerging oral drugs for relapsing-remitting multiple sclerosisClaudio Gasperini
Dipartimento Testa Collo, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
Expert Opin Emerg Drugs 16:697-712. 2011..Nevertheless, in clinical practice DMDs or immunosuppressive treatments are frequently associated with suboptimal response in terms of efficacy and several side effects leading to poor patient adherence...
- Emerging oral drugs for multiple sclerosisClaudio Gasperini
S Camillo Forlanini Hospital, Department of Neuroscience, Viale dell Universita 30, 00185 Rome, Italy
Expert Opin Emerg Drugs 13:465-77. 2008....
- Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective studyEmilia Sbardella
Departments of Neurological Sciences, Sapienza University, Rome, Italy
BMC Neurol 9:54. 2009..We aimed to quantify the contribution of NAbs to the sub-optimal response of IFNbeta treatment...
- Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosisLuca Prosperini
Department of Neurology and Psychiatry, Multiple Sclerosis Centre, S Andrea Hospital, Sapienza University, Rome, Italy
Mult Scler 18:64-71. 2012..To evaluate whether an escalation approach was more effective in suppressing clinical and magnetic resonance imaging (MRI) activity than switching among immunomodulators in relapsing-remitting multiple sclerosis (RRMS) patients...
- Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosisValerio Chiurchiù
Department of Biomedical Sciences, University of Teramo, Teramo, Italy
Ann Neurol 73:626-36. 2013..However, the role of DCs in MS pathogenesis remains poorly understood...
- CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1Luca Battistini
Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Santa Lucia, Rome, Italy
Blood 101:4775-82. 2003..In conclusion, our results show that CD8+, but not CD4+, T cells from patients with RRMS in the acute phase of the disease display increased ability to be recruited in inflamed brain venules...
- Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsClaudio Gasperini
Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy
Ther Clin Risk Manag 6:391-9. 2010..This paper reviews the new oral emerging treatments and presents the available data about the use of cladribine in MS and the future perspective of its clinical use...
- Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosisDaniela F Angelini
Neuroimmunology Unit, Fondazione Santa Lucia I R C C S, Rome, Italy
PLoS Pathog 9:e1003220. 2013..We therefore propose that inability to control EBV infection during inactive MS could set the stage for intracerebral viral reactivation and disease relapse...
- Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosisCarlo Pozzilli
Department of Neurological Sciences, University La Sapienza, Rome, Italy
J Neurol 249:50-6. 2002..o49 for definition II, by the Wilcoxon-Gehan test). Methylprednisilone combined with IFNbeta-1 b reduces the incidence of neutralizing bodies to in terferon-beta during the first year of treatment in MS patients...
- Alexithymia in multiple sclerosis: relationship with fatigue and depressionB Bodini
Department of Neurological Sciences, Sapienza University of Rome, Italy
Acta Neurol Scand 118:18-23. 2008....
- The prevalence of pain in multiple sclerosis: a multicenter cross-sectional studyC Solaro
Department of Neurology, P A Micone Hospital, Genova, Italy
Neurology 63:919-21. 2004..This study underlines the relevance of pain in the clinical history of MS...
- 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidenceC Pozzilli
Department of Neurological Sciences, University La Sapienza, Rome, Italy l it
Eur J Neurol 10:95-7. 2003..Thus, our data indicate that men with MS are prone to develop less inflammatory, but more destructive lesions than women. This study results provides support for a modulation of the MS pathological changes by gender...
- A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-betaA Paolillo
Department of Neurological Sciences, University of Rome La Sapienza, Viale dell Universita 30, 00185 Rome, Italy
Eur J Neurol 9:645-55. 2002....
- Relationship between emotional distress in caregivers and health status in persons with multiple sclerosisC Pozzilli
Department of Neurological Sciences, La Sapienza University, Rome, Italy
Mult Scler 10:442-6. 2004..It suggests that the caregiver is an appropriate and independent target for more focused therapeutic strategies...
- Home based management in multiple sclerosis: results of a randomised controlled trialC Pozzilli
Dipartimento di Scienze Neurologiche, Universita La Sapienza, Rome, Italy
J Neurol Neurosurg Psychiatry 73:250-5. 2002..Home based medical care is a popular alternative to standard hospital care but there is uncertainty about its cost-effectiveness...
- A one-year study on the pharmacodynamic profile of interferon-beta1a in MSF Bagnato
Department of Neurological Sciences, University La Sapienza, Rome, Italy
Neurology 58:1409-11. 2002..Predose levels of beta2-MG increased, the significance of which is as yet unclear...
- Differential diagnosis in multiple sclerosisC Gasperini
Multiple Sclerosis Center, Department of Neuroscience, S. Camillo-Forlanini Hospital, Rome, Italy
Neurol Sci 22:S93-7. 2001..In this paper, I illustrate the diagnostic work-up that the practicing physician should follow when first confronted by a patient suspected of having MS...
- Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosisC Gasperini
Department of Neurology, Ospedale San Camillo-Forlanini, University La Sapienza, Rome, Italy
Mult Scler 7:27-31. 2001..This study shows that the use of different observers and MR scanners has only a small influence on the measured brain volume and does not affect the reproducibility of this measurement greatly...